

CHINA GEWANG BIOTECHNOLOGY, INC.

Form 8-K

July 21, 2016

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

\_\_\_\_\_  
**FORM 8-K**  
\_\_\_\_\_

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 13, 2016**

\_\_\_\_\_  
**CHINA GEWANG BIOTECHNOLOGY, INC.**

(Exact name of registrant as specified in its charter)

**Nevada**  
(State or Other Jurisdiction  
of Incorporation)

**0-54451**  
(Commission  
File Number)

**42-1769584**  
(I.R.S. Employer  
Identification No.)

**Xita 23C, Star International, No. 8 Jinsui Road, Pearl River New Town,**

**Guangzhou Province, P.R. China 510623**

(Address of Principal Executive Office) (Zip Code)

**86-024-2397-4663**

(Registrant's telephone number, including area code)

Edgar Filing: CHINA GEWANG BIOTECHNOLOGY, INC. - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.01**

**Completion of Acquisition of Assets.**

On July 13, 2016 the Registrant's wholly-owned subsidiary, Gewang Selenium Enrichment Information Consulting (Shenzhen) Co., Ltd. ("Gewang Selenium"), exercised its option to purchase all of the registered equity of the Registrant's operating subsidiary, Guangdong Gewang Biotechnology Co., Ltd. ("Guangdong Gewang"). The purchase price paid for the equity was RMB10,000 (approximately \$1,519). The equity was purchased from Shili Zhang, Yun Zeng and Wei Xu. Shili Zhang was the Registrant's CEO until April 8, 2016 and is the father of Mengdi Zhang, who owns 12.7% of the Registrant's outstanding common stock. The other two sellers are not affiliated with the Registrant.

Prior to the acquisition, Gewang Selenium controlled Guangdong Gewang through a series of contractual agreements, which made Guangdong Gewang a variable interest entity, the effect of which was to cause the balance sheet and operating results of Guangdong Gewang to be consolidated with those of Gewang Selenium in the Registrant's financial statements. As a result of the acquisition by Gewang Selenium of registered ownership of Guangdong Gewang, the balance sheet and operating results of Guangdong Gewang will hereafter continue to be consolidated with those of Gewang Selenium as its majority-owned subsidiary. The previous non-controlling interest will be reclassified to additional paid-in-capital.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**China Gewang Biotechnology, Inc.**

Date: July 21, 2016

By: /s/ Li Wang

Li Wang, Chief Executive Officer